CAR T-cell therapy (ImmPACT-Bio)

N/A

Report date: 2025/03/14 16:51:21

Base Information

Drug NameCAR T-cell therapy (ImmPACT-Bio)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionClaudin 18 protein modulatorsTransforming growth factor beta 1 modulators

TargetsClaudin-18 splice variant 2Transforming growth factor beta 1

Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursHematologic Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmPACT Bio USA Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmPACT Bio USA Inc

Inactive CompaniesN/A

Active IndicationsGastroesophageal Junction NeoplasmsHematologic NeoplasmsStomach Neoplasms

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A